tert-butyl N-(1-benzyl-5-methylpiperidin-3-yl)carbamate | 1315366-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl N-(1-benzyl-5-methylpiperidin-3-yl)carbamate
• CAS: 1315366-96-1
• 化学式: C₁₈H₂₈N₂O₂
• mdl: MFCD19381930
• 分子量: 304.4
• InChiKey: XCMHWWZDAXHISG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.611
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (2S,4S)-methanesulfonic acid 2-tert-butoxycarbonylamino-5-methanesulfonyloxy-4-methyl-pentyl ester 生成 tert-butyl N-(1-benzyl-5-methylpiperidin-3-yl)carbamate
  参考文献：
  名称：

  Coupling process for preparing quinolone intermediates

  摘要：

  制备7-环氨基-1-环丙基-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸的过程。适用于此过程的硼酸酯化合物。

  公开号：

  US07456279B2

文献信息

• [EN] PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS PHÉNOXY-PYRIDYL-PYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：GENENTECH INC

  公开号：WO2020056089A1

  公开（公告）日：2020-03-19

  Described herein are phenoxy-pyridyl -pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有肌醇需要酶1（IRE1）调节活性或功能的苯氧基吡啶基嘧啶化合物，其具有Formula I结构或立体异构体、互变异构体或其药用可接受的盐，并具有所述的取代基和结构特征。还描述了包括Formula I化合物的药物组合物和药物，以及使用这种IRE1调节剂的方法，单独或与其他治疗剂联合使用，用于治疗通过雌激素受体介导或依赖的疾病或症状。
• Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
  申请人：Redman-Furey Nancy Lee

  公开号：US20070232650A1

  公开（公告）日：2007-10-04

  The present invention is directed to malate salts of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid, and its polymorphs. The present invention is also directed to pharmaceutical compositions comprising the described salts and polymorphs.

  本发明涉及（3S,5S）-7-[3-氨基-5-甲基哌啶基]-1-环丙基-1,4-二氢-8-甲氧基-4-氧基-3-喹啉羧酸的苹果酸盐及其多晶形式。本发明还涉及包含所述盐和多晶形式的药物组合物。
• Hydride reduction process for preparing quinolone intermediates
  申请人：Hayes Michael Patrick

  公开号：US20070232806A1

  公开（公告）日：2007-10-04

  Hydride process for making acyclic diol intermediates from cyclic intermediates, useful in antibacterial quinolone synthesis.

  从环状中间体制备无环二醇中间体的氢化过程，在抗菌喹诺酮合成中很有用。
• [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2019036377A1

  公开（公告）日：2019-02-21

  The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了某些三环化合物，它们是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病，如癌症和血红蛋白病（例如β地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
• Coupling process for preparing quinolone intermediates
  申请人：Reilly Michael

  公开号：US20070232804A1

  公开（公告）日：2007-10-04

  Process for making 7-cycloamino-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids. Borate ester compounds suitable for use in such process.

  制备7-环氨基-1-环丙基-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸的过程。适用于该过程的硼酸酯化合物。